09:51 AM EST - Isotechnika Pharma Inc. : and Paladin Labs Inc. announced today that they have submitted the dossier and received screening acceptance for Voclera(TM) (voclosporin) for approval in the Canadian market. Voclera is a novel immunosuppressive drug in the class of calcineurin inhibitors and is indicated for the treatment of moderate to severe psoriasis. Isotechnika Pharma Inc.
shares T.ISA are trading up $0.02 at $0.26.
